Phosphodiesterase-5 inhibitors: Action on the signaling pathways of neuroinflammation, neurodegeneration, and cognition

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Peixoto, Christina Alves ^a   Nunes, Ana Karolina Santana ^a,b   Garcia Osta, Ana ^c  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; UDENAFIL; VARDENAFIL; NEUROPROTECTIVE AGENT;

AGING; ANTIOXIDANT ACTIVITY; ASTROCYTE; BLOOD BRAIN BARRIER; CLINICAL TRIAL (TOPIC); COGNITION; DEMYELINATING DISEASE; DRUG EFFECT; HUMAN; MEMORY CONSOLIDATION; MICROGLIA; MOTOR NEURON DISEASE; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NEUROPATHY; NONHUMAN; OLIGODENDROGLIA; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DRUG EFFECTS; GLIA; IMMUNOMODULATION; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BLOOD-BRAIN BARRIER; COGNITION; HUMANS; MICE; NERVE DEGENERATION; NEUROGENESIS; NEUROGLIA; NEUROIMMUNOMODULATION; NEUROPROTECTIVE AGENTS; NUCLEOTIDES, CYCLIC; PHOSPHODIESTERASE 5 INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84950120567     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/940207     Document Type: Review

References (231)

1. J. Kotera, K. Fujishige, and K. Omori, "Immunohistochemical localization of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in rat tissues," Journal of Histochemistry and Cytochemistry, vol. 48, no. 5, pp. 685-693, 2000.
2. W. C. G. Van Staveren, H. W. M. Steinbusch, M. Markerink-Van Ittersum et al., "mRNA expression patterns of the cGMPhydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain," Journal of Comparative Neurology, vol. 467, no. 4, pp. 566-580, 2003.
3. A. Saavedra, A. Giralt, H. Arumis disease," PLoS ONE, vol. 8, no. 9, Article ID e73664, 10 pages, 2013.
4. E. Bollen and J. Prickaerts, "Phosphodiesterases in neurodegenerative disorders," IUBMB Life, vol. 64, no. 12, pp. 965-970, 2012.
5. D. Puzzo and S. Sapienza, "Role of phosphodiesterase 5 in synaptic plasticity and memory Ion channels Ion channels," Journal of Neuropsychiatric Disease and Treatment, vol. 4, no. 2, pp. 371-387, 2008.
6. C. Raposo, R. L. D. A. Luna, A. K. S. Nunes, R. Thome, and C. A. Peixoto, "Role of iNOS-NO-cGMP signaling in modulation of inflammatory and myelination processes," Brain Research Bulletin, vol. 104, pp. 60-73, 2014.
7. J. Prickaerts, A. Sik, W. C. G. Van Staveren et al., "Phosphodiesterase type 5 inhibition improves early memory consolidation of object information," Neurochemistry International, vol. 45, no. 6, pp. 915-928, 2004.
8. O. A. H. Reneerkens, K. Rutten, S. Akkermanet al., "Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: indications for central and peripheral mechanisms," Neurobiology of Learning and Memory, vol. 97, no. 4, pp. 370-379, 2012.
9. S. Akkerman, A. Blokland, N. van Goethem et al., "PDE5 inhibition improves acquisition processes after learning via a central mechanism," Neuropharmacology, vol. 97, pp. 233-239, 2015.
10. D. Puzzo, A. Staniszewski, S. X. Deng et al., "Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-β load in an Alzheimers disease mouse model," The Journal of Neuroscience, vol. 29, no. 25, pp. 8075-8086, 2009.
11. C. Garcia-Barroso, A. Ricobaraza, M. Pascual-Lucas et al., "Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mousemodel of AD," Neuropharmacology, vol. 64, pp. 114-123, 2013.
12. B. V. Zlokovic, "The blood-brain barrier in health and chronic neurodegenerative disorders," Neuron, vol. 57, no. 2, pp. 178-201, 2008.
13. M. A. Erickson, K. Dohi, and W. A. Banks, "Neuroinflammation: a common pathway in CNS diseases as mediated at the blood-brain barrier," NeuroImmunoModulation, vol. 19, no. 2, pp. 121-130, 2012.
14. P. Vajkoczy, M. Laschinger, and B. Engelhardt, " α4-integrin-VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microvessels," The Journal of Clinical Investigation, vol. 108, no. 4, pp. 557-565, 2001.
15. H. Xu, A. Manivannan, J. Liversidge, P. F. Sharp, J. V. Forrester, and I. J. Crane, "Requirements for passage of T lymphocytes across non-inflamed retinal microvessels," Journal of Neuroimmunology, vol. 142, no. 1-2, pp. 47-57, 2003.
16. D. Stanimirovic, A. Shapiro, J. Wong, J. Hutchison, and J. Durkin, "The induction of ICAM-1 in human cerebromicrovascular endothelial cells (HCEC) by ischemia-like conditions promotes enhanced neutrophil/HCEC adhesion," Journal of Neuroimmunology, vol. 76, no. 1-2, pp. 193-205, 1997.
17. D. Kovalovsky, D. Refojo, F. Holsboer, and E. Arzt, "Molecular mechanisms andTh1/Th2 pathways in corticosteroid regulation of cytokine production," Journal of Neuroimmunology, vol. 109, no. 1, pp. 23-29, 2000.
18. B. Engelhardt, "Molecular mechanisms involved in T cell migration across the blood-brain barrier," Journal of Neural Transmission, vol. 113, no. 4, pp. 477-485, 2006.
19. C. K. Petito, J. E. Torres-Munoz, F. Zielger, and M. McCarthy, "Brain CD8+ and cytotoxic T lymphocytes are associated with, and may be specific for, human immunodeficiency virus type 1 encephalitis in patients with acquired immunodeficiency syndrome," Journal of NeuroVirology, vol. 12, no. 4, pp. 272-283, 2006.
20. B. V. Zlokovic, "New therapeutic targets in the neurovascular pathway in Alzheimers disease," Neurotherapeutics, vol. 5, no. 3, pp. 409-414, 2008.
21. R. C. Koehler, R. J. Roman, and D. R. Harder, "Astrocytes and the regulation of cerebral blood flow," Trends in Neurosciences, vol. 32, no. 3, pp. 160-169, 2009.
22. M. Santello and A. Volterra, "TNFα in synaptic function: switching gears," Trends in Neurosciences, vol. 35, no. 10, pp. 638-647, 2012.
23. C. M. Anderson and M. Nedergaard, "Astrocyte-mediated control of cerebral microcirculation," Trends in Neurosciences, vol. 26, no. 7, pp. 340-344, 2003.
24. T. Takano, X. Han, R. Deane, B. Zlokovic, and M. Nedergaard, "Two-photon imaging of astrocytic Ca2+ signaling and the microvasculature in experimental mice models of Alzheimers disease," Annals of the New York Academy of Sciences, vol. 1097, pp. 40-50, 2007.
25. R. Colodner, B. Reznik, V. Gal, H. Yamazaki, H. Hanaki, and R. Kubo, "Evaluation of a novel kit for the rapid detection of extended-spectrum beta-lactamases," European Journal of Clinical Microbiology and Infectious Diseases, vol. 25, no. 1, pp. 49-51, 2006.
26. C. J. Jensen, A. Massie, and J. De Keyser, "Immune players in theCNS: the astrocyte," Journal ofNeuroimmune Pharmacology, vol. 8, no. 4, pp. 824-839, 2013.
27. M. Rothermundt, M. Peters, J. H. M. Prehn, and V. Arolt, "S100B in brain damage and neurodegeneration," Microscopy Research and Technique, vol. 60, no. 6, pp. 614-632, 2003.
28. F. Sedaghat and A. Notopoulos, "S100 protein family and its application in clinical practice," Hippokratia, vol. 12, no. 4, pp. 198-204, 2008.
29. R. H. Selinfreund, S. W. Barger, W. J. Pledger, and L. J. Van Eldik, "Neurotrophic protein S100 β stimulates glial cell proliferation," Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 9, pp. 3554-3558, 1991.
30. A. Nagayach, N. Patro, and I. Patro, "Astrocytic and microglial response in experimentally induced diabetic rat brain," Metabolic Brain Disease, vol. 29, no. 3, pp. 747-761, 2014.
31. Z.-G. Li, W. Zhang, G. Grunberger, and A. A. Sima, "Hippocampal neuronal apoptosis in type 1 diabetes," Brain Research, vol. 946, no. 2, pp. 221-231, 2002.
32. E. C. Hirsch and S. Hunot, "Neuroinflammation in Parkinsons disease: a target for neuroprotection?" The Lancet Neurology, vol. 8, no. 4, pp. 382-397, 2009.
33. A. W. Kraft, X. Hu, H. Yoon et al., "Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice," The FASEB Journal, vol. 27, no. 1, pp. 187-198, 2013.
34. M. Pekny, U. Wilhelmsson, and M. Pekna, "The dual role of astrocyte activation and reactive gliosis," Neuroscience Letters, vol. 565, pp. 30-38, 2014.
35. C. W. Stevens, S. Aravind, S. Das, and R. L. Davis, "Pharmacological characterization of LPS and opioid interactions at the toll-like receptor 4," British Journal of Pharmacology, vol. 168, no. 6, pp. 1421-1429, 2013.
36. D. Ma, S. Jin, E. Li et al., "The neurotoxic effect of astrocytes activated with toll-like receptor ligands," Journal of Neuroimmunology, vol. 254, no. 1-2, pp. 10-18, 2013.
37. M. Bsibsi, A. Nomden, J. M. vanNoort, and W. Baron, "Toll-like receptors 2 and 3 agonists differentially affect oligodendrocyte survival, differentiation, and myelin membrane formation," Journal of Neuroscience Research, vol. 90, no. 2, pp. 388-398, 2012.
38. H. Gonzalez, D. Elgueta, A. Montoya, and R. Pacheco, "Neuroimmune regulation of microglial activity involved in neuroinflammation and neurodegenerative diseases," Journal of Neuroimmunology, vol. 274, no. 1-2, pp. 1-13, 2014.
39. M. D. Norenberg, A. R. Jayakumar, K. V. Rama Rao, and K. S. Panickar, "New concepts in the mechanism of ammoniainduced astrocyte swelling," Metabolic BrainDisease, vol. 22, no. 3-4, pp. 219-234, 2007.
40. A. Martinez Hernandez, K. P. Bell, and M. D. Norenberg, "Glutamine synthetase: glial localization in brain," Science, vol. 195, no. 4284, pp. 1356-1358, 1977.
41. A. R. Jayakumar, K. V. Rama Rao, and M. D. Norenberg, "Neuroinflammation in hepatic encephalopathy: mechanistic aspects," Journal of Clinical and Experimental Hepatology, vol. 5, pp. S21-S28, 2015.
42. D. Haussinger, B. Gorg, R. Reinehr, and F. Schliess, "Protein tyrosine nitration in hyperammonemia and hepatic encephalopathy," Metabolic Brain Disease, vol. 20, no. 4, pp. 285-294, 2005.
43. N. Didier, I. A. Romero, C. Creminon, A. Wijkhuisen, J. Grassi, and A. Mabondzo, "Secretion of interleukin-1β by astrocytes mediates endothelin-1 and tumour necrosis factor-α effects on human brain microvascular endothelial cell permeability," Journal of Neurochemistry, vol. 86, no. 1, pp. 246-254, 2003.
44. J. McAfoose and B. T. Baune, "Evidence for a cytokine model of cognitive function," Neuroscience and Biobehavioral Reviews, vol. 33, no. 3, pp. 355-366, 2009.
45. H. E. De Vries, M. C. M. Blom-Roosemalen, A. G. de Boer, T. J. C. van Berkel, D. D. Breimer, and J. Kuiper, "Effect of endotoxin on permeability of bovine cerebral endothelial cell layers in vitro," Journal of Pharmacology and Experimental Therapeutics, vol. 277, no. 3, pp. 1418-1423, 1996.
46. S. Ding, "Dynamic reactive astrocytes after focal ischemia," Neural Regeneration Research, vol. 9, no. 23, pp. 2048-2052, 2014.
47. M. S. Boran, M. A. Baltrons, and A. Garcia, "The ANP-cGMPprotein kinase G pathway induces a phagocytic phenotype but decreases inflammatory gene expression in microglial cells," Glia, vol. 56, no. 4, pp. 394-411, 2008.
48. C. Y. Shin, W. J. Lee, J. W. Choi et al., "Down-regulation of matrix metalloproteinase-9 expression by nitric oxide in lipopolysaccharide-stimulated rat primary astrocytes," Nitric Oxide-Biology and Chemistry, vol. 16, no. 4, pp. 425-432, 2007.
49. K. Helmut, U.-K. Hanisch, M. Noda, and A. Verkhratsky, "Physiology of microglia," Physiological Reviews, vol. 91, no. 2, pp. 461-553, 2011.
50. I. Bechmann, I. Galea, and V. H. Perry, "What is the blood-brain barrier (not)?" Trends in Immunology, vol. 28, no. 1, pp. 5-11, 2007.
51. I. Bechmann, J. Goldmann, A. D. Kovac et al., "Circulating monocytic cells infiltrate layers of anterograde axonal degeneration where they transforminto microglia," The FASEB Journal, vol. 19, no. 6, pp. 647-649, 2005.
52. R. C. Paolicelli, G. Bolasco, F. Pagani et al., "Synaptic pruning by microglia is necessary for normal brain development," Science, vol. 333, no. 6048, pp. 1456-1458, 2011.
53. A. Bessis, C. Bechade, D. Bernard, and A. Roumier, "Microglial control of neuronal death and synaptic properties," Glia, vol. 55, no. 3, pp. 233-238, 2007.
54. W. J. Streit, "Microglial response to brain injury: a brief synopsis," Toxicologic Pathology, vol. 28, no. 1, pp. 28-30, 2000.
55. S. David and A. Kroner, "Repertoire of microglial and macrophage responses after spinal cord injury," Nature Reviews Neuroscience, vol. 12, no. 7, pp. 388-399, 2011.
56. M. T. Heneka, M. P. Kummer, and E. Latz, "Innate immune activation in neurodegenerative disease," Nature Reviews Immunology, vol. 14, no. 7, pp. 463-477, 2014.
57. C. Cudrici, T. Niculescu, F. Niculescu, M. L. Shin, and H. Rus, "Oligodendrocyte cell death in pathogenesis of multiple sclerosis: protection of oligodendrocytes from apoptosis by complement," Journal of Rehabilitation Research and Development, vol. 43, no. 1, pp. 123-132, 2006.
58. T. W. Lai, S. Zhang, and Y. T. Wang, "Excitotoxicity and stroke: identifying novel targets for neuroprotection," Progress in Neurobiology, vol. 115, pp. 157-188, 2014.
59. R. Karadottir, P. Cavelier, L. H. Bergersen, and D. Attwell, "NMDA receptors are expressed in oligodendrocytes and activated in ischaemia," Nature, vol. 438, no. 7071, pp. 1162-1166, 2005.
60. C. Kaur, G. Rathnasamy, and E.-A. Ling, "Roles of activated microglia in hypoxia induced neuroinflammation in the developing brain and the retina," Journal of Neuroimmune Pharmacology, vol. 8, no. 1, pp. 66-78, 2013.
61. K. Bhaskar, M. Konerth, O. N. Kokiko-Cochran, A. Cardona, R. M. Ransohoff, and B. T. Lamb, "Regulation of tau pathology by the microglial fractalkine receptor," Neuron, vol. 68, no. 1, pp. 19-31, 2010.
62. A. I. Rodriguez-Perez, A. Borrajo, J. Rodriguez-Pallares, M. J. Guerra, and J. L. Labandeira-Garcia, "Interaction between NADPH-oxidase and Rho-kinase in angiotensin II-induced microglial activation," GLIA, vol. 63, no. 3, pp. 466-482, 2015.
63. C. Y. Chang, D.-K. Choi, D. K. Lee, Y. J. Hong, and E. J. Park, "Resveratrol confers protection against rotenone-induced neurotoxicity by modulating myeloperoxidase levels in glial cells," PLoS ONE, vol. 8, no. 4, Article ID e60654, 2013.
64. C. Wang, X. Nie, Y. Zhang et al., "Reactive oxygen species mediate nitric oxide production through ERK/JNK MAPK signaling in HAPI microglia after PFOS exposure," Toxicology and Applied Pharmacology, vol. 288, no. 2, pp. 143-151, 2015.
65. H. L. Hsieh and C. M. Yang, "Role of redox signaling in neuroinflammation and neurodegenerative diseases," BioMed Research International, vol. 2013, Article ID 484613, 18 pages, 2013.
66. S. Ljubisavljevic, "Oxidative stress and neurobiology of demyelination," Molecular Neurobiology, pp. 1-15, 2014.
67. A. Castegna, V. Thongboonkerd, J. B. Klein, B. Lynn, W. R. Markesberyl, and D. A. Butterfield, "Proteomic identification of nitrated proteins in Alzheimers disease brain," Journal of Neurochemistry, vol. 85, no. 6, pp. 1394-1401, 2003.
68. B. I. Giasson, "Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions," Science, vol. 290, no. 5493, pp. 985-989, 2000.
69. L. Wang, M. Chopp, A. Szalad et al., "Sildenafil ameliorates long termperipheral neuropathy in Type II diabetic mice," PLoS ONE, vol. 10, no. 2, Article IDe0118134, 2015.
70. L. J. Peterson and P. M. Flood, "Oxidative stress and microglial cells in Parkinsons disease," Mediators of Inflammation, vol. 2012, Article ID401264, 12 pages, 2012.
71. J. Park, J.-S. Min, B. Kim et al., "Mitochondrial ROS govern the LPS-induced pro-inflammatory response in microglia cells by regulating MAPK and NF-κB pathways," Neuroscience Letters, vol. 584, pp. 191-196, 2015.
72. P. Bezzi, M. Domercq, L. Brambilla et al., "CXCR4-activated astrocyte glutamate release via TNFα: amplification by microglia triggers neurotoxicity," Nature Neuroscience, vol. 4, no. 7, pp. 702-710, 2001.
73. S. Lehnardt, E. Schott, T. Trimbuch et al., "A vicious cycle involving release of heat shock protein 60 frominjured cells and activation of toll-like receptor 4 mediates neurodegeneration in the CNS," Journal of Neuroscience, vol. 28, no. 10, pp. 2320-2331, 2008.
74. H.-M. Gao, H. Zhou, F. Zhang, B. C. Wilson, W. Kam, and J.-S. Hong, "HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration," The Journal of Neuroscience, vol. 31, no. 3, pp. 1081-1092, 2011.
75. G. B. Potter, D. H. Rowitch, and M. A. Petryniak, "Myelin restoration: progress and prospects for human cell replacement therapies," Archivum Immunologiae et Therapiae Experimentalis, vol. 59, no. 3, pp. 179-193, 2011.
76. R. J. M. Franklin and C. ffrench-Constant, "Remyelination in theCNS: frombiology to therapy,"Nature ReviewsNeuroscience, vol. 9, no. 11, pp. 839-855, 2008.
77. M. Geva, Y. Cabilly, Y. Assaf et al., "A mouse model for eukaryotic translation initiation factor 2B-leucodystrophy reveals abnormal development of brain white matter," Brain, vol. 133, no. 8, pp. 2448-2461, 2010.
78. P. R. Matthews, S. L. Eastwood, and P. J. Harrison, "Reduced myelin basic protein and actin-related gene expression in visual cortex in schizophrenia," PLoS ONE, vol. 7, no. 6, Article ID e38211, 2012.
79. Y. Hayashi, N. Nihonmatsu-Kikuchi, S.-I. Hisanaga, X.-J. Yu, and Y. Tatebayashi, "Neuropathological similarities and differences between schizophrenia and bipolar disorder: a flow cytometric postmortem brain study," PLoS ONE, vol. 7, no. 3, Article ID e33019, 2012.
80. K. M. Kinnunen, R. Greenwood, J. H. Powell et al., "White matter damage and cognitive impairment after traumatic brain injury," Brain, vol. 134, no. 2, pp. 449-463, 2011.
81. C. Sievers, P. G. Samann, T. Dose et al., "Macroscopic brain architecture changes andwhitematter pathology in acromegaly: a clinicoradiological study," Pituitary, vol. 12, no. 3, pp. 177-185, 2009.
82. S. J. A. Van Der Werff, C. D. Andela, J. Nienke Pannekoek et al., "Widespread reductions of whitematter integrity in patients with long-term remission of Cushings disease," NeuroImage: Clinical, vol. 4, pp. 659-667, 2014.
83. J. Sun, Y.-Q. Fang, H. Ren et al., "WIN55, 212-2 protects oligodendrocyte precursor cells in stroke penumbra following permanent focal cerebral ischemia in rats,"Acta Pharmacologica Sinica, vol. 34, no. 1, pp. 119-128, 2013.
84. K. Arai and E. H. Lo, "Experimental models for analysis of oligodendrocyte pathophysiology in stroke," Experimental and Translational Stroke Medicine, vol. 1, article 6, 2009.
85. Z. Ahmed, Y. T. Asi, A. J. Lees, T. Revesz, and J. L. Holton, "Identification and quantification of oligodendrocyte precursor cells in multiple system atrophy, progressive supranuclear palsy and parkinsons disease," Brain Pathology, vol. 23, no. 3, pp. 263-273, 2013.
86. E. Gagyi, B. Kormos, K. J. Castellanos et al., "Decreased oligodendrocyte nuclear diameter in Alzheimers disease and lewy body dementia," Brain Pathology, vol. 22, no. 6, pp. 803-810, 2012.
87. M. K. Desai, M. A. Mastrangelo, D. A. Ryan, K. L. Sudol, W. C. Narrow, and W. J. Bowers, "Early oligodendrocyte/myelin pathology in Alzheimers disease mice constitutes a novel therapeutic target," The American Journal of Pathology, vol. 177, no. 3, pp. 1422-1435, 2010.
88. R. Sims, P. Hollingworth, V. Moskvina et al., "Evidence that variation in the oligodendrocyte lineage transcription factor 2 (OLIG2) gene is associated with psychosis in Alzheimers disease," Neuroscience Letters, vol. 461, no. 1, pp. 54-59, 2009.
89. C. Konradi, S. E. Sillivan, and H. B. Clay, "Mitochondria, oligodendrocytes and inflammation in bipolar disorder: evidence from transcriptome studies points to intriguing parallels with multiple sclerosis," Neurobiology of Disease, vol. 45, no. 1, pp. 37-47, 2012.
90. G. J. Francis, J. A. Martinez, W. Q. Liu et al., "Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy," Brain, vol. 131, pp. 3311-3334, 2008.
91. S. Przedborski and H. Ischiropoulos, "Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinsons disease," Antioxidants and Redox Signaling, vol. 7, no. 5-6, pp. 685-693, 2005.
92. G. Saher and S. K. Stumpf, "Cholesterol in myelin biogenesis and hypomyelinating disorders," Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids, vol. 1851, no. 8, pp. 1083-1094, 2015.
93. J. Ritter, T. Schmitz, L.-J. Chew et al., "Neonatal hyperoxia exposure disrupts axon-oligodendrocyte integrity in the subcortical white matter," The Journal of Neuroscience, vol. 33, no. 21, pp. 8990-9002, 2013.
94. J. Scafidi, T. R. Hammond, S. Scafidi et al., "Intranasal epidermal growth factor treatment rescues neonatal brain injury," Nature, vol. 506, no. 7487, pp. 230-234, 2014.
95. H. Shi, X. Hu, R. K. Leak et al., "Demyelination as a rational therapeutic target for ischemic or traumatic brain injury," Experimental Neurology, vol. 272, pp. 17-25, 2015.
96. D. Kremer, P. Kury, and R. Dutta, "Promoting remyelination in multiple sclerosis: current drugs and future prospects," Multiple Sclerosis Journal, vol. 21, no. 5, pp. 541-549, 2015.
97. A. P. Rolo and C. M. Palmeira, "Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress," Toxicology and Applied Pharmacology, vol. 212, no. 2, pp. 167-178, 2006.
98. C. G. Jolivalt, C. A. Lee, K. K. Beiswenger et al., "Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimers disease and correction by insulin," Journal of Neuroscience Research, vol. 86, no. 15, pp. 3265-3274, 2008.
99. E. O. Alvarez, J. Beauquis, Y. Revsin et al., "Cognitive dysfunction and hippocampal changes in experimental type 1 diabetes," Behavioural Brain Research, vol. 198, no. 1, pp. 224-230, 2009.
100. T. Wang, F. Fu, B. Han, L. Zhang, and X. Zhang, "Danshensu ameliorates the cognitive decline in streptozotocin-induced diabetic mice by attenuating advanced glycation end productmediated neuroinflammation," Journal of Neuroimmunology, vol. 245, no. 1-2, pp. 79-86, 2012.
101. J.-Q. Wang, J. Yin, Y.-F. Song et al., "Brain aging and AD-like pathology in streptozotocin-induced diabetic rats," Journal of Diabetes Research, vol. 2014, Article ID 796840, 12 pages, 2014.
102. J. P. Hernandez-Fonseca, J. Rincon, A. Pedreanez et al., "Structural and ultrastructural analysis of cerebral cortex, cerebellum, and hypothalamus from diabetic rats," Experimental Diabetes Research, vol. 2009, Article ID 329632, 12 pages, 2009.
103. Y.-H. Jing, K.-H. Chen, P.-C. Kuo, C.-C. Pao, and J.-K. Chen, "Neurodegeneration in streptozotocin-induced diabetic rats is attenuated by treatment with resveratrol," Neuroendocrinology, vol. 98, no. 2, pp. 116-127, 2013.
104. C. D. Aluise, R. A. S. Robinson, T. L. Beckett et al., "Preclinical Alzheimer disease: brain oxidative stress, Aβ peptide and proteomics," Neurobiology of Disease, vol. 39, no. 2, pp. 221-228, 2010.
105. Z. Cai, B. Zhao, and A. Ratka, "Oxidative stress and betaamyloid protein in Alzheimers disease," NeuroMolecular Medicine, vol. 13, no. 4, pp. 223-250, 2011.
106. D. Galimberti, C. Fenoglio, and E. Scarpini, "Inflammation in neurodegenerative disorders: friend or foe?" Current Aging Science, vol. 1, no. 1, pp. 30-41, 2008.
107. C. Quintana, S. Bellefqih, J. Y. Laval et al., "Study of the localization of iron, ferritin, and hemosiderin in Alzheimers disease hippocampus by analytical microscopy at the subcellular level," Journal of Structural Biology, vol. 153, no. 1, pp. 42-54, 2006.
108. D. L. Schonberg, E. Z. Goldstein, F. R. Sahinkaya, P. Wei, P. G. Popovich, and D. M. McTigue, "Ferritin stimulates oligodendrocyte genesis in the adult spinal cord and can be transferred frommacrophages toNG2 cells in vivo," Journal ofNeuroscience, vol. 32, no. 16, pp. 5374-5384, 2012.
109. B. Parajuli, Y. Sonobe, H. Horiuchi, H. Takeuchi, T. Mizuno, and A. Suzumura, "Oligomeric amyloid β induces IL-1β processing via production of ROS: implication in Alzheimers disease," Cell Death and Disease, vol. 4, article e975, 2013.
110. Z. Cai, G. Chen, W. He, M. Xiao, and L.-J. Yan, "Activation of mTOR: a culprit of Alzheimers disease?" Neuropsychiatric Disease and Treatment, vol. 11, pp. 1015-1030, 2015.
111. G. Behrendt, K. Baer, A. Buffo et al., "Dynamic changes in myelin aberrations and oligodendrocyte generation in chronic amyloidosis in mice and men," Glia, vol. 61, no. 2, pp. 273-286, 2013.
112. S. Akterin, R. F. Cowburn, A. Miranda-Vizuete et al., "Involvement of glutaredoxin-1 and thioredoxin-1 in β-amyloid toxicity and Alzheimers disease," Cell Death and Differentiation, vol. 13, no. 9, pp. 1454-1465, 2006.
113. L. Guo, L. Luo, R. Ju et al., "Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMPphosphodiesterases," European Journal of Pharmacology, vol. 746, pp. 14-21, 2015.
114. G. Azizi, S. S. Navabi, A. Al-Shukaili, M. H. Seyedzadeh, R. Yazdani, and A. Mirshafiey, "The role of inflammatory mediators in the pathogenesis of Alzheimers disease," Sultan Qaboos UniversityMedical Journal, vol. 15, no. 3, pp. e305-e316, 2015.
115. I. M. Stromnes, L. M. Cerretti, D. Liggitt, R. A. Harris, and J. M. Goverman, "Differential regulation of central nervous system autoimmunity by TH1 and TH17 cells," Nature Medicine, vol. 14, no. 3, pp. 337-342, 2008.
116. E. M. L. Chastain, D. S. Duncan, J. M. Rodgers, and S. D. Miller, "The role of antigen presenting cells in multiple sclerosis," Biochim Biophys Acta, vol. 1812, no. 2, pp. 265-274, 2011.
117. B. Almolda, B. Gonzalez, and B. Castellano, "Antigen presentation in EAE: role of microglia, macrophages and dendritic cells," Frontiers in Bioscience, vol. 16, no. 3, pp. 1157-1171, 2011.
118. L. Peferoen, M. Kipp, P. van der Valk, J. M. van Noort, and S. Amor, "Oligodendrocyte-microglia cross-talk in the central nervous system," Immunology, vol. 141, no. 3, pp. 302-313, 2014.
119. M. Bradl and H. Lassmann, "Oligodendrocytes: biology and pathology," Acta Neuropathologica, vol. 119, no. 1, pp. 37-53, 2010.
120. J. M. Vela, E. Molina-Holgado, A. Arevalo-Martin, G. Almazan, and C. Guaza, "Interleukin-1 regulates proliferation and differentiation of oligodendrocyte progenitor cells," Molecular and Cellular Neuroscience, vol. 20, no. 3, pp. 489-502, 2002.
121. G. Ramesh, S. Benge, B. Pahar, and M. T. Philipp, "A possible role for inflammation in mediating apoptosis of oligodendrocytes as induced by the Lyme disease spirochete Borrelia burgdorferi," Journal of Neuroinflammation, vol. 9, article 72, 2012.
122. N. G. Carlson, M. A. Rojas, J. W. Redd et al., "Cyclooxygenase-2 expression in oligodendrocytes increases sensitivity to excitotoxic death," Journal of Neuroinflammation, vol. 7, article 25, 2010.
123. K. Domek-Lopacinska and J. B. Strosznajder, "Cyclic GMP metabolism and its role in brain physiology," Journal of Physiology and Pharmacology, vol. 56, supplement 2, pp. 15-34, 2005.
124. J. Fass, S. Gehler, P. Sarmiere, P. Letourneau, and J. R. Bamburg, "Regulating filopodial dynamics through actin-depolymerizing factor/cofilin," Anatomical Science International, vol. 79, no. 4, pp. 173-183, 2004.
125. Q. Cui and K.-F. So, "Involvement of cAMP in neuronal survival and axonal regeneration," Anatomical Science International, vol. 79, no. 4, pp. 209-212, 2004.
126. S. Gerlo, R. Kooijman, I. M. Beck, K. Kolmus, A. Spooren, and G. Haegeman, "Cyclic AMP: a selective modulator of NF-κB action," Cellular and Molecular Life Sciences, vol. 68, no. 23, pp. 3823-3841, 2011.
127. J. D. Corbin and S. H. Francis, "Cyclic GMPphosphodiesterase-5: target of sildenafil,"The Journal of Biological Chemistry, vol. 274, no. 20, pp. 13729-13732, 1999.
128. L. M. S. Dusse, A. J. Cooper, and B. A. Lwaleed, "Tissue factor and nitric oxide: a controversial relationship!," Journal of Thrombosis and Thrombolysis, vol. 23, no. 2, pp. 129-133, 2007.
129. N. O. Rizzo, E. Maloney, M. Pham et al., "Reduced NOcGMP signaling contributes to vascular inflammation and insulin resistance induced by high-fat feeding," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 4, pp. 758-765, 2010.
130. D. J. Lefer, S. P. Jones, W. G. Girod et al., "Leukocyte-endothelial cell interactions in nitric oxide synthase-deficient mice," American Journal of Physiology-Heart and Circulatory Physiology, vol. 276, no. 6, pp. H1943-H1950, 1999.
131. M.-J. Sanz, M. J. Hickey, B. Johnston et al., "Neuronal nitric oxide synthase (NOS) regulates leukocyte-endothelial cell interactions in endothelial NOS deficient mice," British Journal of Pharmacology, vol. 134, no. 2, pp. 305-312, 2001.
132. A. Ahluwalia, P. Foster, R. S. Scotland et al., "Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent downregulation of P-selectin expression and leukocyte recruitment," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 5, pp. 1386-1391, 2004.
133. T. Aizawa, H. Wei, J. M. Miano, J.-I. Abe, B. C. Berk, and C. Yan, "Role of phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in vascular smooth muscle cells," Circulation Research, vol. 93, no. 5, pp. 406-413, 2003.
134. N. C. Weber, S. B. Blumenthal, T. Hartung, A. M. Vollmar, and A. K. Kiemer, "ANP inhibits TNF-α-induced endothelialMCP-1 expression-involvement of p38 MAPK and MKP-1," Journal of Leukocyte Biology, vol. 74, no. 5, pp. 932-941, 2003.
135. S. Minguet, M. Huber, L. Rosenkranz, W. W. A. Schamel, M. Reth, and T. Brummer, "Adenosine and cAMP are potent inhibitors of theNF-κB pathway downstreamof immunoreceptors," European Journal of Immunology, vol. 35, no. 1, pp. 31-41, 2005.
136. X. Wu, K. Mahadev, L. Fuchsel, R. Ouedraogo, S.-Q. Xu, and B. J. Goldstein, "Adiponectin suppresses IκB kinase activation induced by tumor necrosis factor-α or high glucose in endothelial cells: role of cAMP and AMP kinase signaling," American Journal of Physiology-Endocrinology and Metabolism, vol. 293, no. 6, pp. E1836-E1844, 2007.
137. P. J. Kamthong and M.-C. Wu, "Inhibitor of nuclear factor-αB induction by cAMP antagonizes interleukin-1-induced human macrophage-colony-stimulating-factor expression," Biochemical Journal, vol. 356, no. 2, pp. 525-530, 2001.
138. M. Spiecker, H.-B. Peng, and J. K. Liao, "Inhibition of endothelial vascular cell adhesion molecule-1 expression by nitric oxide involves the induction and nuclear translocation of IκBα," The Journal of Biological Chemistry, vol. 272, no. 49, pp. 30969-30974, 1997.
139. J. R. Matthews, C. H. Botting, M. Panico, H. R. Morris, and R. T. Hay, "Inhibition ofNF-κBDNAbinding by nitric oxide," Nucleic Acids Research, vol. 24, no. 12, pp. 2236-2242, 1996.
140. I. M. Grumbach, W. Chen, S. A. Mertens, and D. G. Harrison, "A negative feedback mechanism involving nitric oxide and nuclear factor κ-B modulates endothelial nitric oxide synthase transcription," Journal ofMolecular and Cellular Cardiology, vol. 39, no. 4, pp. 595-603, 2005.
141. R. R. Fiscus, "Involvement of cyclic GMP and protein kinase G in the regulation of apoptosis and survival in neural cells," NeuroSignals, vol. 11, no. 4, pp. 175-190, 2002.
142. A. Nagai-Kusuhara, M. Nakamura, H. Mukuno, A. Kanamori, A. Negi, and G. M. Seigel, "cAMP-responsive element binding protein mediates a cGMP/protein kinase G-dependent antiapoptotic signal induced by nitric oxide in retinal neuro-glial progenitor cells," Experimental Eye Research, vol. 84, no. 1, pp. 152-162, 2007.
143. K. Merz, S. Herold, and D. C. Lie, "CREB in adult neurogenesis-master and partner in the development of adult-born neurons?" European Journal of Neuroscience, vol. 33, no. 6, pp. 1078-1086, 2011.
144. R. S. Bitner, "Cyclic AMP response element-binding protein (CREB) phosphorylation: amechanistic marker in the development of memory enhancing Alzheimers disease therapeutics," Biochemical Pharmacology, vol. 83, no. 6, pp. 705-714, 2012.
145. C. Cunha, R. Brambilla, and K. L. Thomas, "A simple role for BDNF in learning and memory?" Frontiers in Molecular Neuroscience, vol. 3, article 1, 2010.
146. A. Brunet, S. R. Datta, and M. E. Greenberg, "Transcriptiondependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway," Current Opinion in Neurobiology, vol. 11, no. 3, pp. 297-305, 2001.
147. A. I. Santos, B. P. Carreira, R. J. Nobre, C. M. Carvalho, and I. M. Araujo, "Stimulation of neural stem cell proliferation by inhibition of phosphodiesterase 5," Stem Cells International, vol. 2014, Article ID878397, 13 pages, 2014.
148. E. Fuchs and E. Gould, "In vivo neurogenesis in the adult brain: regulation and functional implications," European Journal of Neuroscience, vol. 12, no. 7, pp. 2211-2214, 2000.
149. R. L. Djavadian, "Serotonin and neurogenesis in the hippocampal dentate gyrus of adult mammals," Acta Neurobiologiae Experimentalis, vol. 64, no. 2, pp. 189-200, 2004.
150. R. L. Zhang, M. Chopp, C. Roberts et al., "Sildenafil enhances neurogenesis and oligodendrogenesis in ischemic brain of middle-agedmouse," PLoSONE, vol. 7, no. 10, Article IDe48141, 2012.
151. L. Zhang, R. L. Zhang, Y. Wang et al., "Functional recovery in aged and young rats after embolic stroke," Stroke, vol. 36, pp. 847-852, 2005.
152. R. Zhang, Y. Wang, L. Zhang et al., "Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats," Stroke, vol. 33, no. 11, pp. 2675-2680, 2002.
153. L. Zhang, Z. Zhang, R. L. Zhang et al., "Tadalafil, a longacting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke," Brain Research, vol. 1118, no. 1, pp. 192-198, 2006.
154. P. Gulati and N. Singh, "Tadalafil enhances the neuroprotective effects of ischemic postconditioning in mice, probably in a nitric oxide associated manner," Canadian Journal of Physiology and Pharmacology, vol. 92, no. 5, pp. 418-426, 2014.
155. S. Gul, B. Bahadir, V. Hanci et al., "Effect of vardenafil on cerebral vasospasm following experimental subarachnoid hemorrhage in rats," Journal of Clinical Neuroscience, vol. 17, no. 8, pp. 1038-1041, 2010.
156. S. Zhao, L. Zhang, G. Lian et al., "Sildenafil attenuates LPSinduced pro-inflammatory responses through down-regulation of intracellular ROS-related MAPK/NF-κB signaling pathways in N9 microglia," International Immunopharmacology, vol. 11, no. 4, pp. 468-474, 2011.
157. A. Aversa, C. Vitale, M. Volterrani et al., "Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes," Diabetic Medicine, vol. 25, no. 1, pp. 37-44, 2008.
158. E. Mandosi, E. Giannetta, T. Filardi et al., "Endothelial dysfunction markers as a therapeutic target for Sildenafil treatment and effects on metabolic control in type 2 diabetes," Expert Opinion on Therapeutic Targets, 2015.
159. A. Varma, A. Das, N. N. Hoke, D. E. Durrant, F. N. Salloum, and R. C. Kukreja, "Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice," PLoS ONE, vol. 7, no. 9, Article ID e45243, 2012.
160. A. Das, D. Durrant, F. N. Salloum, L. Xi, and R. C. Kukreja, "PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer," Pharmacology andTherapeutics, vol. 147, pp. 12-21, 2015.
161. S. Koka, A. Das, F. N. Salloum, and R. C. Kukreja, "Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice," Free Radical Biology and Medicine, vol. 60, pp. 80-88, 2013.
162. A. Aversa, R. Bruzziches, D. Francomano, M. Natali, and A. Lenzi, "Testosterone and phosphodiesterase type-5 inhibitors: new strategy for preventing endothelial damage in internal and sexual medicine?" Therapeutic Advances in Urology, vol. 1, no. 4, pp. 179-197, 2009.
163. D. A. Greene, "Effects of aldose reductase inhibitors on the progression of nerve fiber damage in diabetic neuropathy," Journal of Diabetes and Its Complications, vol. 6, no. 1, pp. 35-38, 1992.
164. G. Hackett, "PDE5 inhibitors in diabetic peripheral neuropathy," International Journal of Clinical Practice, vol. 60, no. 9, pp. 1123-1126, 2006.
165. C. S. Patil, V. P. Singh, S. Singh, and S. K. Kulkarni, "Modulatory effect of the PDE-5 inhibitor sildenafil in diabetic neuropathy," Pharmacology, vol. 72, no. 3, pp. 190-195, 2004.
166. L. Wang, M. Chopp, A. Szalad et al., "Phosphodiesterase-5 is a therapeutic target for peripheral neuropathy in diabetic mice," Neuroscience, vol. 193, pp. 399-410, 2011.
167. B. Halter, J.-L. Gonzalez de Aguilar, F. Rene et al., "Oxidative stress in skeletal muscle stimulates early expression of Rad in a mouse model of amyotrophic lateral sclerosis," Free Radical Biology and Medicine, vol. 48, no. 7, pp. 915-923, 2010.
168. M. Ikawa, H. Okazawa, T. Tsujikawa et al., "Increased oxidative stress is related to disease severity in the ALS motor cortex: a PET study," Neurology, vol. 84, no. 20, pp. 2033-2039, 2015.
169. M. T. Carri, C. Valle, F. Bozzo, and M. Cozzolino, "Oxidative stress and mitochondrial damage: importance in non-SOD1 ALS," Frontiers in Cellular Neuroscience, vol. 9, article 41, 2015.
170. T. Nakamizo, J. Kawamata, K. Yoshida et al., "Phosphodiesterase inhibitors are neuroprotective to cultured spinal motor neurons," Journal of Neuroscience Research, vol. 71, no. 4, pp. 485-495, 2003.
171. A. Giralt, M. Puigdellivol, O. Carreton et al., "Long-term memory deficits in Huntingtons disease are associated with reduced CBP histone acetylase activity," Human Molecular Genetics, vol. 21, no. 6, pp. 1203-1216, 2012.
172. C. Giampa, E. Montagna, C. Dato, M. A. B. Melone, G. Bernardi, and F. R. Fusco, "Systemic delivery of recombinant brain derived neurotrophic factor (bdnf) in the r6/2 mouse model of huntingtons disease," PLoS ONE, vol. 8, no. 5, Article IDe64037, 2013.
173. Z. DeMarch, C. Giampa, S. Patassini, G. Bernardi, and F. R. Fusco, "Beneficial effects of rolipram in the R6/2 mouse model of Huntingtons disease," Neurobiology of Disease, vol. 30, no. 3, pp. 375-387, 2008.
174. F. R. Fusco and C. Giampa, "Phosphodiesterases as therapeutic targets for Huntingtons disease," Current Pharmaceutical Design, vol. 21, no. 3, pp. 365-377, 2015.
175. E. Puerta, I. Hervias, L. Barros-Minones et al., "Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF," Neurobiology of Disease, vol. 38, no. 2, pp. 237-245, 2010.
176. K. Benardais, A. Kotsiari, J. Skuljec et al., "Cuprizone bis(cyclohexylidenehydrazide)] is selectively toxic for mature oligodendrocytes," Neurotoxicity Research, vol. 24, no. 2, pp. 244-250, 2013.
177. P. Pifarre, J. Prado, M. A. Baltrons et al., "Sildenafil (Viagra) ameliorates clinical symptoms and neuropathology in a mouse model ofmultiple sclerosis," Acta Neuropathologica, vol. 121, no. 4, pp. 499-508, 2011.
178. A. K. D. S. Nunes, C. Raposo, R. L. D. A. Luna, M. A. da Cruz-Hofling, and C. A. Peixoto, "Sildenafil (Viagra) down regulates cytokines and prevents demyelination in a cuprizone-induced MS mouse model," Cytokine, vol. 60, no. 2, pp. 540-551, 2012.
179. C. Raposo, A. K. D. S. Nunes, R. L. D. A. Luna, S. M. D. R. Araujo, M. A. Da Cruz-Hofling, and C. A. Peixoto, "Sildenafil (Viagra) protective effects on neuroinflammation: the role of iNOS/NO system in an inflammatory demyelination model," Mediators of Inflammation, vol. 2013, Article ID321460, 11pages, 2013.
180. P. Pifarre, M. Gutierrez-Mecinas, J. Prado et al., "Phosphodiesterase 5 inhibition at disease onset prevents experimental autoimmune encephalomyelitis progression through immunoregulatory and neuroprotective actions," Experimental Neurology, vol. 251, pp. 58-71, 2014.
181. E. R. Kandel, "The molecular biology of memory storage: a dialogue between genes and synapses," Science, vol. 294, no. 5544, pp. 1030-1038, 2001.
182. L. R. Squire and S. H. Barondes, "Memory impairment during prolonged training in mice given inhibitors of cerebral protein synthesis," Brain Research, vol. 56, pp. 215-225, 1973.
183. T. V. P. Bliss and G. L. Collingridge, "A synaptic model of memory: long-term potentiation in the hippocampus," Nature, vol. 361, no. 6407, pp. 31-39, 1993.
184. R. C. Malenka and R. A. Nicoll, "Long-term potentiation-a decade of progress?" Science, vol. 285, no. 5435, pp. 1870-1874, 1999.
185. U. Frey, Y. Y. Huang, and E. R. Kandel, "Effects of cAMP simulate a late stage of LTP in hippocampal CA1 neurons," Science, vol. 260, no. 5114, pp. 1661-1664, 1993.
186. P. K. Stanton and J. M. Sarvey, "Blockade of long-term potentiation in rat hippocampal CA1 region by inhibitors of protein synthesis," Journal of Neuroscience, vol. 4, no. 12, pp. 3080-3088, 1984.
187. R. D. Blitzer, T. Wong, R. Nouranifar, R. Iyengar, and E. M. Landau, "Postsynaptic cAMP pathway gates early LTP in hippocampal CA1 region," Neuron, vol. 15, no. 6, pp. 1403-1414, 1995.
188. M. Zhuo, Y. Hu, C. Schultz, E. R. Kandel, and R. D. Hawkins, "Role of guanylyl cyclase and cGMP-dependent protein kinase in long-term potentiation," Nature, vol. 368, no. 6472, pp. 635-639, 1994.
189. O. Arancio, E. R. Kandel, and R. D. Hawkins, "Activitydependent long-term enhancement of transmitter release by presynaptic 3′, 5′-cyclic GMP in cultured hippocampal neurons," Nature, vol. 376, no. 6535, pp. 74-80, 1995.
190. B. J. Bacskai, B. Hochner, M. Mahaut-Smith et al., "Spatially resolved dynamics of cAMP and protein kinase a subunits in Aplysia sensory neurons," Science, vol. 260, no. 5105, pp. 222-226, 1993.
191. P. K. Dash, B. Hochner, and E. R. Kandel, "Injection of the cAMP-responsive element into the nucleus of Aplysia sensory neurons blocks long-term facilitation," Nature, vol. 345, no. 6277, pp. 718-721, 1990.
192. Y.-F. Lu, E. R. Kandel, and R. D. Hawkins, "Nitricoxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus," Journal of Neuroscience, vol. 19, no. 23, pp. 10250-10261, 1999.
193. Y.-F. Lu and R. D. Hawkins, "Ryanodine receptors contribute to cGMP-induced late-phase LTP and CREB phosphorylation in the hippocampus," Journal of Neurophysiology, vol. 88, no. 3, pp. 1270-1278, 2002.
194. I. Izquierdo, L. R. M. Bevilaqua, J. I. Rossato, J. S. Bonini, J. H. Medina, and M. Cammarota, "Different molecular cascades in different sites of the brain control memory consolidation," Trends in Neurosciences, vol. 29, no. 9, pp. 496-505, 2006.
195. K. Rutten, J. Prickaerts, M. Hendrix, F. J. van der Staay, A. Sik, and A. Blokland, "Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors," European Journal of Pharmacology, vol. 558, no. 1-3, pp. 107-112, 2007.
196. R. D. Hawkins, "No honey, I dont remember," Neuron, vol. 16, pp. 465-467, 1996.
197. Y. Matsumoto, S. Unoki, H. Aonuma, and M. Mizunami, "Critical role of nitric oxide-cGMP cascade in the formation of cAMP-dependent long-term memory," Learning and Memory, vol. 13, no. 1, pp. 35-44, 2006.
198. R. Bourtchouladze, T. Abel, N. Berman, R. Gordon, K. Lapidus, and E. R. Kandel, "Different training procedures recruit either one or two critical periods for contextual memory consolidation, each of which requires protein synthesis and PKA," Learning and Memory, vol. 5, no. 4-5, pp. 365-374, 1998.
199. S. Impey, K. Obrietan, S. T. Wonget al., "Cross talkbetweenERK and PKA is required for Ca2+ stimulation of CREB-dependent transcription and ERK nuclear translocation," Neuron, vol. 21, no. 4, pp. 869-883, 1998.
200. T. Gudi, S. M. Lohmann, and R. B. Pilz, "Regulation of gene expression by cyclic GMP-dependent protein kinase requires nuclear translocation of the kinase: identification of a nuclear localization signal," Molecular and Cellular Biology, vol. 17, no. 9, pp. 5244-5254, 1997.
201. T. Gudi, I. Huvar, M. Meinecke, G. R. Boss, and B. P. Renate, "Regulation of gene expression by cGMP-dependent protein kinase,"The Journal of Biological Chemistry, vol. 271, pp. 4597-4600, 1996.
202. K. T. Ota, V. J. Pierre, J. E. Ploski, K. Queen, and G. E. Schafe, "The NO-cGMP-PKG signaling pathway regulates synaptic plasticity and fear memory consolidation in the lateral amygdala via activation of ERK/MAP kinase," Learning andMemory, vol. 15, no. 10, pp. 792-805, 2008.
203. K. T. Ota, M. S. Monsey, M. S. Wu, G. J. Young, and G. E. Schafe, "Synaptic plasticity and NO-cGMP-PKG signaling coordinately regulate ERK-driven gene expression in the lateral amygdala and in the auditory thalamus following Pavlovian fear conditioning.," Learning and Memory, vol. 17, no. 4, pp. 221-235, 2010.
204. Z. Zhao, Z. Wang, Y. Gu, R. Feil, F. Hofmann, and L. Ma, "Regulate axon branching by the cyclic GMP pathway via inhibition of glycogen synthase kinase 3 in dorsal root ganglion sensory neurons," Journal of Neuroscience, vol. 29, no. 5, pp. 1350-1360, 2009.
205. F.-Q. Zhou, J. Zhou, S. Dedhar, Y.-H. Wu, and W. D. Snider, "NGF-induced axon growth is mediated by localized inactivation of GSK-3β and functions of the microtubule plus end binding protein APC," Neuron, vol. 42, no. 6, pp. 897-912, 2004.
206. H. M. Roder and M. L. Huttona, "Microtubule-associated protein tau as a therapeutic target in neurodegenerative disease," Expert Opinion on Therapeutic Targets, vol. 11, no. 4, pp. 435-442, 2014.
207. A. Garcia-Osta, M. Cuadrado-Tejedor, C. Garcia-Barroso, J. Oyarzabal, and R. Franco, "Phosphodiesterases as therapeutic targets for Alzheimers disease," ACS Chemical Neuroscience, vol. 3, no. 11, pp. 832-844, 2012.
208. O. A. H. Reneerkens, K. Rutten, H. W. M. Steinbusch, A. Blokland, and J. Prickaerts, "Selective phosphodiesterase inhibitors: a promising target for cognition enhancement," Psychopharmacology, vol. 202, no. 1-3, pp. 419-443, 2009.
209. B. Gong, O. V. Vitolo, F. Trinchese, S. Liu, M. Shelanski, and O. Arancio, "Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment," The Journal of Clinical Investigation, vol. 114, no. 11, pp. 1624-1634, 2004.
210. M. Hiramatsu, O. Takiguchi, A. Nishiyama, and H. Mori, "Cilostazol prevents amyloid β peptide23-25-induced memory impairment and oxidative stress in mice," British Journal of Pharmacology, vol. 161, pp. 1899-1912, 2010.
211. M. Cuadrado-Tejedor, I. Hervias, A. Ricobaraza et al., "Sildenafil restores cognitive function without affecting β-amyloid burden in amousemodel ofAlzheimers disease," British Journal of Pharmacology, vol. 164, no. 8, pp. 2029-2041, 2011.
212. S. H. Park, J. H. Kim, S. S. Bae et al., "Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid β accumulation," Biochemical and Biophysical Research Communications, vol. 408, no. 4, pp. 602-608, 2011.
213. K. Rutten, E. L. Van Donkelaar, L. Ferrington et al., "Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats," Neuropsychopharmacology, vol. 34, no. 8, pp. 1914-1925, 2009.
214. A. Palmeri, L. Privitera, S. Giunta, C. Loreto, and D. Puzzo, "Inhibition of phosphodiesterase-5 rescues age-related impairment of synaptic plasticity and memory," Behavioural Brain Research, vol. 240, pp. 11-20, 2013.
215. L. Orejana, L. Barros-Minones, J. Jordan, E. Puerta, and N. Aguirre, "Sildenafil ameliorates cognitive deficits and tau pathology in a senescence-accelerated mouse model," Neurobiology of Aging, vol. 33, no. 3, pp. 625. e11-625. e20, 2012.
216. Y. S. Shim, C.-U. Pae, K. J. Cho, S. W. Kim, J. C. Kim, and J. S. Koh, "Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study," International Journal of Impotence Research, vol. 26, no. 2, pp. 76-80, 2014.
217. Y. S. Shim, C.-U. Pae, S. W. Kim, H. W. Kim, J. C. Kim, and J. S. Koh, "Effects of repeated dosing with Udenafil (Zydena) on cognition, somatization and erection in patients with erectile dysfunction: a pilot study," International Journal of Impotence Research, vol. 23, no. 3, pp. 109-114, 2011.
218. F. Jin, Q.-H. Gong, Y.-S. Xu et al., "Icariin, a phoshphodiesterase-5 inhibitor, improves learning and memory in APP/PS1 transgenic mice by stimulation of NO/cGMP signalling," International Journal of Neuropsychopharmacology, vol. 17, no. 6, pp. 871-881, 2014.
219. M. Chalimoniuk and J. B. Strosznajder, "Agingmodulates nitric oxide synthesis and cGMP levels in hippocampus and cerebellum: effects of amyloid β peptide," Molecular and Chemical Neuropathology, vol. 35, no. 1-3, pp. 77-95, 1999.
220. K. U. Domek-Lopacinska and J. B. Strosznajder, "Cyclic GMP and nitric oxide synthase in aging and Alzheimers disease," Molecular Neurobiology, vol. 41, no. 2-3, pp. 129-137, 2010.
221. M. Matsushita, T. Yamamoto, and H. Gemba, "The role of astrocytes in the development of hepatic encephalopathy," Neuroscience Research, vol. 34, no. 4, pp. 271-280, 1999.
222. D. Puzzo, O. Vitolo, F. Trinchese, J. P. Jacob, A. Palmeri, and O. Arancio, "Amyloid-β peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity," The Journal of Neuroscience, vol. 25, no. 29, pp. 6887-6897, 2005.
223. W. L. Bonkale, B. Winblad, R. Ravid, and R. F. Cowburn, "Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimers disease," Neuroscience Letters, vol. 187, no. 1, pp. 5-8, 1995.
224. M. A. Baltrons, C. E. Pedraza, M. T. Heneka, and A. Garcia, "β-amyloid peptides decrease soluble guanylyl cyclase expression in astroglial cells," Neurobiology ofDisease, vol. 10, no. 2, pp. 139-149, 2002.
225. A. Ugarte, F. Gil-Bea, C. Garcia-Barroso et al., "Decreased levels of guanosine 3′, 5′-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimers disease," Neuropathology and Applied Neurobiology, vol. 41, no. 4, pp. 471-482, 2015.
226. J. Shi, W. Qian, X. Yin et al., "Cyclic AMP-dependent protein kinase regulates the alternative splicing of tau exon 10: a mechanism involved in tau pathology of Alzheimer disease," Journal of Biological Chemistry, vol. 286, no. 16, pp. 14639-14648, 2011.
227. L. Orejana, L. Barros-Minones, J. Jordan et al., "Sildenafil decreases BACE1 and cathepsin B levels and reduces APP amyloidogenic processing in the SAMP8 mouse," The Journals of Gerontology Series A: Biological Sciences andMedical Sciences, vol. 70, no. 6, pp. 675-685, 2015.
228. F. Li, H. X. Dong, Q. H. Gong, Q. Wu, F. Jin, and J. S. Shi, "Icariin decreases both APP and Aβ levels and increases neurogenesis in the brain of Tg2576 mice," Neuroscience, vol. 304, pp. 29-35, 2015.
229. D. Puzzo, C. Loreto, S. Giunta et al., "Effect of phosphodiesterase-5 inhibition on apoptosis and beta amyloid load in aged mice," Neurobiology of Aging, vol. 35, no. 3, pp. 520-531, 2014.
230. J. Fiorito, F. Saeed, H. Zhang et al., "Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimers disease," European Journal of Medicinal Chemistry, vol. 60, pp. 285-294, 2013.
231. L. Zhu, J.-Y. Yang, X. Xue et al., "A novel phosphodiesterase-5 inhibitor: yonkenafil modulates neurogenesis, gliosis to improve cognitive function and ameliorates amyloid burden in an APP/PS1 transgenic mice model,"Mechanisms of Ageing and Development, vol. 150, pp. 34-45, 2015.